Sampurna Chatterjee, PhD, MBA
CANCER SCIENTIST, TAKEDA PHARMACEUTICALS
Chatterjee is a translational scientist at Takeda Pharmaceuticals, where she brings innovative cures to patients with advanced and difficult-to-treat cancers. Prior to this, she developed novel therapeutics for deadly brain cancers at the Harvard Medical School and Massachusetts General Hospital where she actively worked with young patients and their families to spread awareness about this deadly disease. Previously, Chatterjee identified prognostic biomarkers for clinical trials in advanced lung cancer patients at the Max Planck Society in Cologne, Germany. Alongside serving as an editor in scientific journals, Chatterjee is a professional mentor for early-career scientists at MGH and MIT offering high-level guidance for long-term career development, grant writing, public speaking, and networking.
Chatterjee is passionate about transforming society by making science open, inclusive, and accessible. She was the co-vice chair of the Massachusetts General Hospital Postdoctoral Association (MGPA), where she advocated to provide a platform for research and career development for scientists. Currently, she serves on the Board of Directors of several non-profits to foster and promote an inclusive environment for all, particularly those underrepresented in science and medicine and those struggling with sexuality and gender identity.
Chatterjee has been invited to serve as a mentor in multiple national and international symposiums, and workshops, such as the NUCLEATE, NIH, and NPA IMPACT programs- all with an overarching goal to inspire and train scientists and entrepreneurs from vulnerable communities and backgrounds to become future leaders. She has been nominated as a ‘Woman of Inspiration 2022’ for profoundly influencing global healthcare and community.